Exenatide vs Lixisenatide

Exenatide is a GLP-1 receptor agonist available as Byetta (a twice-daily injection) and Bydureon (a once-weekly injection), both made by AstraZeneca and approved for treating type 2 diabetes. Lixisenatide is another GLP-1 receptor agonist sold as Adlyxin (a once-daily injection) and Soliqua (a combination injection with insulin glargine), made by Sanofi, and also approved for type 2 diabetes. The main differences are how often they’re taken and whether they’re used alone or combined with other medications.

AI summary of the sources below.